Kauko et al. demonstrated that genetic knockdown of SET, CIP2A or PME1 globally increases the sensitivity of cancer cells to a panel of kinase inhibitors, while knockdown of the PP2A A subunit drives global therapeutic resistance (41). The gene discussed is SET; the disease is cancer.